Owens & Minor, Inc. — 2016 Form 10-K Summary
Filing identity: The supplied filing is for Owens & Minor, Inc. (NYSE: OMI), not Accendra Health Inc. It covers the fiscal year ended December 31, 2016; it is not a standalone fourth-quarter filing.
Business context and reporting period
Owens & Minor provides healthcare product distribution, logistics and related services in the United States and Europe, as well as surgical and procedural kitting and sourcing. In 2016, the company reorganized and reported three segments: Domestic, International, and Clinical & Procedural Solutions (CPS). Prior-year segment results were recast.
Financial performance and liquidity
| Metric | 2016 | 2015 | Change |
|---|---|---|---|
| Net revenue | $9.723 billion | $9.773 billion | Down 0.5% |
| Gross margin | $1.187 billion; 12.21% | $1.215 billion; 12.43% | Down 2.2%; margin down 22 bps |
| Operating earnings (GAAP) | $199.6 million; 2.05% | $200.4 million; 2.05% | Down 0.4% |
| Net income | $108.8 million | $103.4 million | Up 5.2% |
| Diluted EPS | $1.76 | $1.65 | Up $0.11 |
| Adjusted diluted EPS (non-GAAP) | $2.05 | $2.00 | Up $0.05 |
| Cash from operating activities | $186.9 million | $269.6 million | Down 30.7% |
Adjusted operating earnings were $224.3 million, versus $227.3 million in 2015; adjusted operating margin was 2.31%, versus 2.33%. The company recorded $24.7 million of acquisition-related and exit and realignment charges in 2016 ($17.8 million after tax, or $0.29 per diluted share).
At year-end, cash and cash equivalents were $185.5 million, total debt was $569.4 million, and shareholders’ equity was $960.0 million. The $450 million revolving credit facility had no borrowings and approximately $445 million available after letters of credit. Current assets were $1.962 billion and current liabilities were $1.035 billion. Capital expenditures were $30.1 million. Cash dividends paid were $63.4 million and share repurchases were $71.0 million.
Material changes versus the prior comparable period
- Revenue declined primarily because of the exit of a large domestic customer and unfavorable foreign exchange. Domestic revenue increased 0.2%; International declined 7.8%; CPS declined 4.0%.
- Gross margin fell due to lower manufacturer product-price-change income, the domestic customer exit, and $11.9 million of unfavorable currency translation. Management said competitive and customer cost pressures were expected to continue.
- DS&A declined 2.4% to $970.4 million, reflecting cost controls, lower fuel costs, efficiency gains and favorable currency effects.
- Segment operating earnings were $165.5 million Domestic (up from $162.9 million), $5.6 million International (up from $3.2 million), and $53.8 million CPS (down from $61.9 million). CPS cited lower revenue and production capacity and workforce challenges.
- Operating cash flow decreased from $269.6 million to $186.9 million. Year-end cash increased by $24.5 million, compared with a $104.2 million increase in 2015.
Outlook, risks and unusual items
- Management expected the lost domestic customer to continue negatively affecting 2017 revenue and gross margin. It also anticipated additional 2017 repositioning charges and said CPS production challenges could continue.
- In April 2016, the company announced the loss of its largest integrated delivery network customer, which had generated approximately $525 million of revenue in 2015. The filing also reports that GPO-member hospital sales under Vizient, Premier and HPG contracts represented approximately 81% of 2016 consolidated revenue.
- Key risks include intensifying distribution pricing pressure, customer and supplier concentration, healthcare cost and reimbursement changes, international currency and Brexit uncertainty, regulatory and privacy obligations, cyber and systems disruption, and product liability or recall exposure.
- The company had $24.7 million in acquisition-related and exit and realignment charges. It stated that new actions in 2017 could result in charges similar to prior years. Pending legal matters were described as ordinary and incidental; management considered the probable-loss accrual not material.
- Management said available cash, operating cash flow and revolver capacity should be sufficient for foreseeable needs. It approved a first-quarter 2017 dividend of $0.2575 per share, a 1% increase from the 2016 quarterly rate.
Important facts for investors to verify
- Confirm the issuer identity: the filing is Owens & Minor, not Accendra Health Inc.
- Track customer attrition and the effect of the lost $525 million-revenue customer on 2017 revenue, margins and cash conversion.
- Review gross-margin trends, supplier incentive income and exposure to GPOs and major suppliers.
- Assess whether CPS capacity and workforce issues improve and whether segment earnings recover.
- Monitor operating cash flow, working capital (including DSO of 23.1 days), debt, covenant compliance and planned buybacks and dividends.
- Consider the distinction between GAAP results and management’s non-GAAP adjusted measures, including recurring realignment charges.
KPMG issued an unqualified opinion on the consolidated financial statements and internal control over financial reporting; management also concluded disclosure controls and internal controls were effective at year-end.